Lewis Martyn, Chesterton Linda S, Sim Julius, Mallen Christian D, Hay Elaine M, van der Windt Daniëlle A
Arthritis Research UK Primary Care Centre, Institute of Primary Care and Health Sciences, Keele University, Keele, Staffordshire, United Kingdom.
PLoS One. 2015 Aug 28;10(8):e0135460. doi: 10.1371/journal.pone.0135460. eCollection 2015.
The TATE trial was a multicentre pragmatic randomized controlled trial of supplementing primary care management (PCM)-consisting of a GP consultation followed by information and advice on exercises-with transcutaneous electrical nerve stimulation (TENS), to reduce pain intensity in patients with tennis elbow. This paper reports the health economic evaluation.
Adults with new diagnosis of tennis elbow were recruited from 38 general practices in the UK, and randomly allocated to PCM (n = 120) or PCM plus TENS (n = 121). Outcomes included reduction in pain intensity and quality-adjusted-life-years (QALYs) based on the EQ5D and SF6D. Two economic perspectives were evaluated: (i) healthcare-inclusive of NHS and private health costs for the tennis elbow; (ii) societal-healthcare costs plus productivity losses through work absenteeism. Mean outcome and cost differences between the groups were evaluated using a multiple imputed dataset as the base case evaluation, with uncertainty represented in cost-effectiveness planes and through probabilistic cost-effectiveness acceptability curves). Incremental healthcare cost was £33 (95%CI -40, 106) and societal cost £65 (95%CI -307, 176) for PCM plus TENS. Mean differences in outcome were: 0.11 (95%CI -0.13, 0.35) for change in pain (0-10 pain scale); -0.015 (95%CI -0.058, 0.029) for QALYEQ5D; 0.007 (95%CI -0.022, 0.035) for QALYSF6D (higher score differences denote greater benefit for PCM plus TENS). The ICER (incremental cost effectiveness ratio) for the main evaluation of mean difference in societal cost (£) relative to mean difference in pain outcome was -582 (95%CI -8666, 8113). However, incremental ICERs show differences in cost-effectiveness of additional TENS, according to the outcome being evaluated.
Our findings do not provide evidence for or against the cost-effectiveness of TENS as an adjunct to primary care management of tennis elbow.
TATE试验是一项多中心实用随机对照试验,旨在研究在初级保健管理(PCM)——包括全科医生会诊以及随后的运动信息和建议——基础上,加用经皮电刺激神经疗法(TENS),以减轻网球肘患者的疼痛强度。本文报告了健康经济学评估结果。
从英国38家普通诊所招募新诊断为网球肘的成年人,并随机分配至PCM组(n = 120)或PCM加TENS组(n = 121)。结局指标包括基于EQ5D和SF6D的疼痛强度降低情况以及质量调整生命年(QALY)。评估了两个经济学视角:(i)医疗保健——包括国民保健服务(NHS)和网球肘的私人医疗费用;(ii)社会——医疗保健成本加上因旷工导致的生产力损失。以多重填补数据集作为基础病例评估,评估两组之间的平均结局和成本差异,成本效益平面和概率成本效益可接受性曲线表示不确定性。PCM加TENS的增量医疗保健成本为33英镑(95%CI -40, 106),社会成本为65英镑(95%CI -307, 176)。结局的平均差异为:疼痛变化(0 - 10疼痛量表)为0.11(95%CI -0.